Subject and method: This was a cross-sectional, prospective study with longitudinal follow-up, no control group. The study was conducted on 44 stage II, III BC patients receiving NAC with dd AC-T regimen at Department of General Oncology, Institute of Oncology, 108 Military Central Hospital from June 2018 to August 2022.